Quick Answer
Xeris Biopharma Holdings, Inc. reported R&D Expense of $31.16 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $31.16M | +21.9% |
| 2024 | $25.56M | +14.4% |
| 2023 | $22.34M | +6.6% |
| 2022 | $20.97M | -16.7% |
| 2021 | $25.16M | +20.3% |
| 2020 | $20.92M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.48M | +27.1% | -7.1% |
| June 30, 2025 | $8.05M | +39.9% | +3.9% |
| March 31, 2025 | $7.75M | -0.9% | +31.7% |
| September 30, 2024 | $5.89M | +17.0% | +2.2% |
| June 30, 2024 | $5.76M | -5.4% | -26.4% |
| March 31, 2024 | $7.82M | +61.7% | +55.4% |
| September 30, 2023 | $5.03M | -16.7% | -17.3% |
| June 30, 2023 | $6.09M | +63.7% | +25.8% |
- Xeris Biopharma Holdings, Inc. showed an increase of +21.9% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Xeris Biopharma Holdings, Inc.’s r&d expense has grown by 49.0% (from $20.92 million to $31.16 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: